Insider Trading Alert - CVLT, THC And MAC Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Aug. 15, 2014, 95 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $116.62 to $15,679,644.00.

Highlighted Stocks Traded by Insiders:

CommVault Systems (CVLT) - FREE Research Report

Geday Armando, who is Director at CommVault Systems, sold 8,000 shares at $52.79 on Aug. 15, 2014. Following this transaction, the Director owned 63,901 shares meaning that the stake was reduced by 11.13% with the 8,000-share transaction.

Walker David F, who is Director at CommVault Systems, sold 2,000 shares at $52.59 on Aug. 15, 2014. Following this transaction, the Director owned 14,067 shares meaning that the stake was reduced by 12.45% with the 2,000-share transaction.

The shares most recently traded at $53.88, up $1.29, or 2.39% since the insider transaction. Historical insider transactions for CommVault Systems go as follows:

  • 4-Week # shares bought: 2,000
  • 4-Week # shares sold: 290
  • 12-Week # shares bought: 2,000
  • 12-Week # shares sold: 290
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 4,321

The average volume for CommVault Systems has been 633,000 shares per day over the past 30 days. CommVault Systems has a market cap of $2.4 billion and is part of the technology sector and computer software & services industry. Shares are down 29.36% year-to-date as of the close of trading on Friday.

CommVault Systems, Inc., together with its subsidiaries, provides data and information management software applications and related services primarily in North America, Europe, Australia, and Asia. The company has a P/E ratio of 41.0. Currently, there are 8 analysts who rate CommVault Systems a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CVLT - FREE

TheStreet Quant Ratings rates CommVault Systems as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and unimpressive growth in net income. Get the full CommVault Systems Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Tenet Healthcare (THC) - FREE Research Report

Kangas Edward A, who is Director at Tenet Healthcare, sold 12,000 shares at $44.29 on Aug. 15, 2014. Following this transaction, the Director owned 24,198 shares meaning that the stake was reduced by 33.15% with the 12,000-share transaction.

Reynolds Britt T, who is Pres. of Hospital Operations at Tenet Healthcare, sold 8,028 shares at $58.49 on Aug. 15, 2014. Following this transaction, the Pres. of Hospital Operations owned 17,197 shares meaning that the stake was reduced by 31.83% with the 8,028-share transaction.

The shares most recently traded at $59.22, up $0.73, or 1.24% since the insider transaction. Historical insider transactions for Tenet Healthcare go as follows:

  • 4-Week # shares bought: 6,250
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 6,250
  • 12-Week # shares sold: 10,000
  • 24-Week # shares bought: 6,250
  • 24-Week # shares sold: 45,624

The average volume for Tenet Healthcare has been 1.6 million shares per day over the past 30 days. Tenet Healthcare has a market cap of $5.7 billion and is part of the health care sector and health services industry. Shares are up 39.13% year-to-date as of the close of trading on Friday.

Tenet Healthcare Corporation, an investor-owned health care services company, primarily operates acute care hospitals and related health care facilities in the United States. Currently, there are 9 analysts who rate Tenet Healthcare a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on THC - FREE

TheStreet Quant Ratings rates Tenet Healthcare as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and poor profit margins. Get the full Tenet Healthcare Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Macerich (MAC) - FREE Research Report

O Hern Thomas E, who is Senior EVP, Treasurer & CFO at Macerich, sold 5,000 shares at $66.30 on Aug. 15, 2014. Following this transaction, the Senior EVP, Treasurer & CFO owned 61,267 shares meaning that the stake was reduced by 7.55% with the 5,000-share transaction.

The shares most recently traded at $65.11, down $1.19, or 1.83% since the insider transaction. Historical insider transactions for Macerich go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 10,000
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 66,458

The average volume for Macerich has been 604,200 shares per day over the past 30 days. Macerich has a market cap of $9.3 billion and is part of the financial sector and real estate industry. Shares are up 11.16% year-to-date as of the close of trading on Friday.

The Macerich Company is an independent real estate investment trust. The firm invests in the real estate markets of the United States. The stock currently has a dividend yield of 3.77%. The company has a P/E ratio of 115.3. Currently, there are 6 analysts who rate Macerich a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MAC - FREE

TheStreet Quant Ratings rates Macerich as a buy. The company's strengths can be seen in multiple areas, such as its good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat weak growth in earnings per share. Get the full Macerich Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again

GE Confirms $11.1 Billion Transportation Merger With Wabtec

GE Confirms $11.1 Billion Transportation Merger With Wabtec